Hand, Foot and Mouth Disease
Conditions
Keywords
Inactivated Enterovirus Type 71 (EV71) Vaccine, Sequential vaccination, Immunity, Safety
Brief summary
The purpose of this study is to evaluate the immunogenicity and safety of sequential vaccination of two EV71 inactived vaccines in healthy infants aged 6-35 months.
Detailed description
This study is a opened,randomized and controlled phase Ⅳ clinical trial. The purpose of this study is to evaluate the immunogenicity and safety of sequential vaccination of two EV71 inactived vaccines in healthy infants aged 6-35 months. EV71 inactived vaccines(Vero cells）was manufactured by Sinovac Biotech Co., Ltd and EV71 inactived vaccines(Human diploid cells）was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.300 infants aged between 6-35 months will be randomly assigned into experimental group in the ratio 1:1:1:1.The experimental group 1 received two doses EV71 inactived vaccines(Vero cells）on day 0 and 30. The experimental group 2 received two doses EV71 inactived vaccines (Human diploid cells）on day 0 and 30. The experimental group 3 received one dose EV71 inactived vaccines (Vero cells）on day 0 and one dose EV71 inactived vaccines (Human diploid cells）on day 30.The experimental group 4 received one dose EV71 inactived vaccines (Human diploid cells）on day 0 and one dose EV71 inactived vaccines (Vero cells）on day 30. To evaluate the immunogenicity of the vaccine, venous blood will be collected for the EV71 neutralizing antibody detection prior to vaccination and 30 days after the 2nd dose vaccination.
Interventions
BIOLOGICALEV71 inactived vaccine（Vero cells）
The EV71 inactived vaccine（Vero cells） was manufactured by Sinovac Biotech Co., Ltd.
BIOLOGICALEV71 inactived vaccine（Human diploid cells）
The EV71 inactived vaccine（Human diploid cells） was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.
Sponsors
Shandong Province Centers for Disease Control and Prevention
Sinovac Biotech Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Months to 35 Months
Healthy volunteers
Yes
Inclusion criteria
* Healthy volunteer aged 6-35 months; * Proven legal identity; * Guardians of the participants should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study.
Exclusion criteria
* Prior vaccination with EV71 vaccine; * History of hand，foot and mouth disease; * Allergy to gentamicin; history of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria,difficulty in breathing, angioneurotic edema, pain, etc; * Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc; * Autoimmune diseases or immunodeficiency/immunosuppression; * Severe neurological disorders (epilepsy, convulsions or convulsions) or psychosis; * History of thyroidectomy, absence of spleen, functional absence of spleen, and any circumstances leading to absence of spleen or splenectomy; * Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders; * Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) in the past 6 months; * Receipt of any of the following products: 1. Blood product within 3 months prior to study entry; 2. Any live attenuated vaccine within 14 days prior to study entry; 3. Any subunit vaccine or inactivated vaccine within 7 days prior to study entry; 4. Any other study drugs within 30 days prior to study entry; * Acute disease or acute stage of chronic disease within 7 days prior to study entry; * Axillary temperature \> 37.0℃; * Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The seroconversion rates (SCR) of the EV71 neutralizing antibody calculated based on the cutoff value of 1:8. | 30 days after two doses | Subjects whose pre-immune EV71 antibody level \< 1:8 and post-immune antibody level ≥ 1:8, or those whose pre-immune antibody level ≥ 1:8 and the increase of post-immune EV71 antibody level ≥ 4 folds are considered seroconverted |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of solicited local and general adverse events after each does | 0-7 days after each dose | After each dose, a 30-minute safety observation will be conducted immediately. The body temperature, solicited local and general adverse events (AE) on day 0-7 were reported. Each AE case will be reviewed by the investigator to determine whether or not it was an adverse reaction (The vaccination-related AE). |
| Incidence of serious adverse events (SAEs) during the period of safety monitoring | 0-30 days after each dose | Serious adverse events (SAEs) will be collected during the period of safety monitoring after each dose. |
| The incidences of adverse reactions after each does | 0-30 days after each dose | After each dose, a 30-minute safety observation will be conducted immediately. The body temperature, solicited local and general adverse events (AE) on day 0-7 were reported. Unsolicited adverse events on day 0-30 were also reported. Each AE case will be reviewed by the investigator to determine whether or not it was an adverse reaction (The vaccination-related AE). |
| The Geometric mean titer (GMT) of the EV71 neutralizing antibody | 30 days after two doses | The GMT 30 days of each group after two doses. |
| The geometric mean fold increase (GMI) of the EV71 neutralizing antibody | 30 days after two doses | The GMI 30 days of each group after two doses. |
| EV71 neutralizing antibody positive rate of each group after two doses. | 30 days after two doses | Subjects whose post-immune antibody level ≥ 1:8 are considered antibody positive. |
Countries
China
Outcome results
None listed